We have a new FDA-approved oral SERD combo for HR+ mBC!
In evERA, led by @elmayermd, giredestrant (vs SoC ET) + everolimus nearly doubled PFS (10 vs 5.5 mo) and ORR (27% vs 14%) in patients with ESR1 mutations.
Another important option for our patients! fda.gov/drugs/cancer-approva…
This!👇🏻Agree wholeheartedly with this patient-centric approach! Therapy should be tailored to the patient as we consistently see this is not a “one-size fits all” space
CLEOPATRA did not test a fixed number of taxane cycles. We eventually landed on 6-8 cycles due to cumulative neuropathy.
DB09 did not test a fixed number of T-DXd cycles. However, the lack of neuropathy with T-DXd provided the opportunity for more prolonged administration. The opportunity to keep the tumor under the pressure of cytotoxic treatment for longer.
The effect of this can be seen in the DB09 PFS curves. They overlap for 4 months. They separate thereafter. 📉 Right after the taxane is stopped in the control arm, and maintenance is started, more patients start progressing. Progressions that are prevented in the T-DXd arm. And HER2+ disease progressions can be nasty.
So, how many cycles of T-DXd should we give?
There’s no magic number. We should let the disease features and patient preferences guide us.
-Shorter duration for lower-risk disease. Longer duration if high-risk (recurrent, visceral, CNS, PI3K mut).
-Shorter duration for disease that rapidly achieve complete response. Longer duration for disease that shrinks less.
-Shorter duration for patients that experience bothersome side effects. Longer duration for patients that tolerate well.
Determining the duration of T-DXd really takes the whole art of medicine.
We’re out of the one-size fits all era in HER2+ breast cancer.
nature.com/articles/s41571-0…
3 practice refinements after #ESMO26:
1. Always offer screening brain MRI at metastatic diagnosis (HER2+/TN) and offer 1L ADCs in case of BM
2. Consider adding tucatinib to HP after local therapy for brain-only PD while on 1L HP maintenance
3. Limit sequential TOPO1 ADCs
Dr. Erica Mayer (@elmayermd) at the #ESMO26 HR+ breast cancer poster session showcasing a recent expert consensus on the management of ribociclib-associated liver-related adverse events in HR+/HER2− #BreastCancer.
TROPION-Breast02, brain mets subgroup at ESMO 2026. First-line Dato-DXd vs chemo in mTNBC, n=61.
CNS PFS 9.5 vs 2.6 mo, HR 0.27. Intracranial ORR 62.5% vs 37.5%. Longest intracranial response about 27 mo.
In TNBC, brain mets come early and we usually treat them locally first. This makes me ask whether a patient with small asymptomatic lesions could start Dato-DXd and defer /combine SRS
Not ready for clinic. This is a post hoc subgroup, n=30 with untreated brain mets. And even on Dato-DXd, median OS was 11.6 mo with brain mets vs 23.7 mo without. The CNS benefit is real; the prognosis is still poor. The answer needs a dedicated CNS trial. #bcsm#ESMO26@myESMO
We now have prospective data with TOPO1 ADC sequencing from:
- SATEEN (#ESMOBreast26)
- HER3-DXd (#ESMOBreast26)
- SWITCH (upcoming #ESMO26)
All validate prior retrospective data, showing that TOPO1 ADC resistance is not overcome by target switch.
New payloads urgently needed.
#ESMO26 | SWITCH – Phase II
In mBC progressing after ADC therapy, switching the target antigen while continuing with the same TOP1 inhibitor payload class resulted in ORRs of only 0–8.3%.
Although the sample size was small and the patient population heterogeneous, changing the target antigen alone does not appear sufficient to overcome resistance.
Vaginal estrogen after breast cancer: is it safe? 🩺
New JCO OP review: low-dose vaginal estrogen keeps serum estradiol in the postmenopausal range. Observational data show no ↑ recurrence or mortality, incl. ER+ & tamoxifen.
doi.org/10.1200/OP-26-00625
SERENA-6 showed that ctDNA-guided switching before radiographic progression can extend PFS in breast cancer. Worth remembering that lung cancer already ran a similar study:
-APPLE (EORTC LCG-1613) monitored plasma T790M on gefitinib and switched to osimertinib at molecular progression. Median PFS was comparable to switching at radiographic progression (22.0 vs 20.2 mo); only 17% of patients ever switched on ctDNA before their scans changed.
-The 6–3 ODAC vote and @NeilVasan highlights the dilemma: nobody doubts the drug works, the question is whether acting at molecular progression beats waiting for the scan. Same idea, different tumor, still unsettled...
@FDA granted accelerated approval for camizestrant today based on SERENA-6: switching therapy when an ESR1 mutation appears in ctDNA, before scans show progression. This is resistance defined, drugged, and tracked at the bedside.
I served as Chair of the Oncologic Drugs Advisory Committee (ODAC) on this trial. My recent @JAMAOnc piece discussed the vote and regulatory issues around detecting cancer before it is seen: jamanetwork.com/journals/jam…
FDA grants accelerated approval to Etcamah (camizestrant) + CDK4/6i (abemaciclib, palbociclib, ribociclib) for HR+/HER2- advanced BC upon ESR1 mutation detected during AI + CDK4/6i therapy, by FDA-authorized test.
Pro: mPFS 16 vs 9.2 mo per label. In SERENA-6, final PFS2 25.7 vs 19.1 mo (HR 0.63) and 46% lower risk of deterioration in global health status/QOL.
Con: Accelerated approval, OS immature, confirmatory trials required. Boxed warning for irregular heart rhythm with certain concomitant meds, plus bradycardia.
First trial to intervene on molecular resistance in breast cancer before clinical PD.
#bcsm
After #ASCO25 Plenary, Camizestrant is now @US_FDA ✅ based off #SERENA6: PhIII, Camizestrant + CDK4/6i vs AI + CDK4/6i for emerging ESR1m before progression.
- mPFS2: 25.7mos vs. 19.1mos (HR: 0.63)
- mPFS: 16.8mos vs. 9.2mos (HR: 0.45)
#OncTwitter#bcsm#MedX@OncoAlert
JUST IN: @FDA approves camizestrant, an ER antagonist, in combo with a CDK4/6 inhibitor in HR+, HER2 - metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor, based on #SERENA6 trial. On April 30, ODAC voted 3-6 against.
@ASCOPost@ASCOascopost.com/news/september-…
Iza-bren (Yizekang®) met primary endpoint (PFS) in a pre-specified interim analysis of the PANKU-Breast01 (aka BL-B01D1-306) trial for patients with HR+/HER2- breast cancer.
5th phase III trial to hit the primary endpoint for iza-bren!
asia.tools.euroland.com/tool…
🧤 Hand-Foot Syndrome Prevention: A Network Meta-analysis
Can we finally prevent chemotherapy-induced Hand-Foot Syndrome?
Key findings:
🔹 19 randomized trials involving 2,192 patients compared 13 preventive strategies.
🥇 Topical diclofenac 1% gel had the strongest overall evidence, reducing both Grade ≥2 HFS and overall HFS.
🌿 Topical silymarin showed the greatest efficacy signal but needs larger confirmatory trials.
💊 Celecoxib was effective; 400 mg pyridoxine showed benefit, whereas lower doses did not.
⚠️ Urea cream alone showed no consistent benefit, and Mapisal was associated with increased HFS risk.
Bottom line: For patients starting capecitabine, topical diclofenac 1% gel is currently the best-supported strategy to prevent Hand-Foot Syndrome.
#MedicalOncology#SupportiveCare#Capecitabine#HandFootSyndrome#NetworkMetaAnalysis#JAMADermatology#EvidenceBasedMedicine#CancerCare#MVOnco
Approximately 30% of HER2+ breast cancers harbor PIK3CA mutations. In this interesting report just published in @ESMO_Open, gedatolisib + trastuzumab yielded an ORR of 43% and PFS 6 months for pretreated, PIK3CAm, HER2+ MBC. Key toxicity: stomatitis. esmoopen.com/article/S2059-7…
Gedatolisib now approved for PIK3CAwt ER+ MBC. Very active regimen, many open questions:
- triplet vs doublet. I’d favor doublet to optimize the benefit/risk ratio
- IV infusions clearly add burden, shared decision making is key
- if ESR1 mutant, SERD combos may be prioritized
VIKTORIA-1 published in JCO, showing promising activity of fulvestrant/gedatolisib +/-palbo in PIK3CAwt HR+ MBC, at the expense of weekly IV injections (3wk on 1wk off) and most patients experiencing stomatitis. 2 treatment-related deaths with the triplet. ascopubs.org/doi/10.1200/JCO…
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events
nature.com/articles/s41523-0…
Pembrolizumab plus chemotherapy continues to demonstrate durable clinical benefit as first-line treatment for advanced triple-negative #BreastCancer with PD-L1 CPS ≥10, based on additional analyses from the phase 3 🔑KEYNOTE-355 trial.
Patients who discontinued chemotherapy 🧪before pembrolizumab maintained progression-free and overall survival comparable to the overall study population. Immune-mediated adverse events were generally manageable with supportive care, and patients experiencing these events showed a numerical trend toward improved efficacy, further supporting this treatment approach.
@hoperugo@maria_gion@JavierCortesMD@LoiSher@wilburpan@oncoAlert 🚨